1. Home
  2. Category
  3. Diagnosis and Screening

Treatment Decision Making

CNE Article

Biosimilars: Exploring the History, Science, and Progress

Joseph D. Tariman
CJON 2018, 22(5), 5-12 DOI: 10.1188/18.CJON.S1.5-12
Background: Biosimilars provide opportunities for improving healthcare access and outcomes and reducing overall healthcare costs for patients with cancer. Objectives: The purpose of this article is to explore the history of biosimilars, regulatory pathways, and barriers to biosimilar approval. This...
3
Average: 3 (1 vote)
Read this Article
CNE Article

Clinical Trials: Nursing Roles During the Approval Process and Pharmacovigilance of Biosimilars

Jazel Dolores Sugay
CJON 2018, 22(5), 27-32 DOI: 10.1188/18.CJON.S1.27-32
Background: The development of biosimilars is occurring more rapidly as patents on biologics expire. Oncology nurses will have an integral role in the new era of biosimilars regarding administration and education. Objectives: The purpose of this article is to review the role of the oncology nurse...
0
No votes yet
Read this Article
CNE Article

Approval Process: An Overview of Biosimilars in the Oncology Setting

Lisa Sowinski-Raff
CJON 2018, 22(5), 13-18 DOI: 10.1188/18.CJON.S1.13-18
Background: Following approval of the Biologics Price Competition and Innovation Act of 2009, biosimilars are gradually entering the market in the United States. With the introduction of more biosimilars into the marketplace, all healthcare providers should be familiar with the approval and...
5
Average: 5 (2 votes)
Read this Article
Genetics & Genomics

Decision Making: Approaches and Tools to Respond to Ethical Issues in Genetic and Genomic Nursing

Mary Beth Steck
CJON 2018, 22(4), 386-389 DOI: 10.1188/18.CJON.386-389
Competent genetic and genomic nursing practice requires the incorporation of various ethical approaches, or tools, into patient decision making. Using different decision-making approaches, which converge to answer an ethical issue, nurses can be confident that their judgment is justified. A lack of...
0
No votes yet
Read this Article
Online Exclusive Article

Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events

Kathleen Clifford
Amanda Copeland
Gregory Knutzen
Ellen Samuelson
Laurie Grove
Karen Schiavo
CJON 2018, 22(4), E103-E114 DOI: 10.1188/18.CJON.E103-E114
Background: Brentuximab vedotin (BV) is an antibody–drug conjugate that targets CD30-expressing cells. Objectives: This article assesses the occurrence and management of the most frequent and clinically relevant BV-associated adverse events (AEs), with a focus on Hodgkin lymphoma and systemic...
5
Average: 5 (1 vote)
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.